MagForce AG : Publishes First Quarterly Shareholder Letter

Berlin, Germany, July 24, 2013 - MagForce AG (Frankfurt, Xetra: MF6), a leading medical device company in the area of nanotechnology with a focus on oncology, published today its first "Shareholder Letter".

Subsequently, such shareholder letters shall be published quarterly in order to keep shareholders well informed about the ongoing developments and progress.

The shareholder letter can be downloaded here:
http://www.magforce.de/en/presse-investoren/aktionaersbriefe.html:
http://www.magforce.de/en/presse-investoren/aktionaersbriefe.html

Key points are

• Personal introduction of Dr. Ben Lipps, designated CEO and Chairman of the Management Board
• Focus on recurrent Glioblastoma Multiform Cancer (GBM) and Prostate Cancer
• Details to GBM post-marketing study
• Search for strategic partners in Emerging Markets.

About MagForce AG
MagForce AG is a leading medical device company in the field of nanomedicine in oncology, listed in the entry standard (MF6). The Company's proprietary, NanoTherm^® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm^®, NanoPlan^®, and NanoActivator(TM) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm^®, NanoPlan^®, and NanoActivator(TM) are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com:
http://www.magforce.com/.

Full Resume Dr. Ben Lipps
Dr. Ben J. Lipps became Chairman and Chief Executive Officer of the Management Board of Fresenius Medical Care in May 1999. In December 2012 he stepped down as Chairman of the Management Board and CEO. During his term, Fresenius Medical Care's sales tripled from 3.8 to 12.8 billion dollars, and the annual net profit grew 6 times to 1.1 billion dollars.
He was also Chief Executive Officer of Fresenius Medical Care North America until February 2004. He was President, Chief Executive Officer, Chief Operating Officer and a director of Fresenius USA from October 1989 through February 2004, and served in various capacities with Fresenius USA's predecessor from 1985 through 1989.

He earned his master's and doctoral degrees at the Massachusetts Institute of Technology in chemical engineering. Before joining the Fresenius Group in 1985, Dr. Lipps held several research management positions in various companies, among them with DOW Chemical.

Disclaimer
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Contact:
Anne Hennecke
MC Services AG

T +49 89 210228-18
F +49 89 210228-88
M +49 151 12 555 759

Email: anne.hennecke@mc-services.eu:
mailto:anne.hennecke@mc-services.eu